Gene therapy by tumor cells transfected with genes of costimulatory molecular and cytokines
Gene therapy by tumor cells transfected with genes of costimulatory molecular and cytokines
批准号:
07671333
负责人:
OKINAGA Kota
金额:
$1.66万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1995
资助国家:
日本
项目状态:
已结题
起止时间:
1995 至 1996
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In this study, we evaluated the antitumor immunity of tumor vaccine transfected IL-2, GM-CSF,or costimulatory molecule B7 gene using the adenovirus vector. Furthermore, tumor cells were cultured with IFN-gamma to increase the expression of MHC class I antigen.The expressions of IL-2 and GM-CSF protein in the cells infected with recombinant adenovirus were examined by Western blot and microscopic fluorecent analysis. The secretion of these cytokines from the cells was detected by ELISA assay. From the flow cytometry analysis, the cell surface expression of B7 protein was extremely high due to the infection of recombinant adenovirus transduced B7 gene, and the expression of MHC class I antigen of cell surface increased due to the preculture with IFN-gamma . For the animal study, mice were divided into 7 groups as follows : (1) IL2+B7+IFN-gamma (2) IL2+B7 (3) IL2 (4) B7 (5) IFN-gamma (6) non-transduced tumor cells (7) PBS.In the prevention model of tumor growth (day-7 tumor vaccine), IL2+B7+IFN-gamma, IL2+B7, and IL2 groups showed the significant decreases of tumor volume as compared to the nontransduced tumor cells and PBS groups (P<0.01), and the survival rates were 50%, 37.5%, and 25%, respectively. In the therapeutic model of the tumor (day 1 tumor vaccine), IL2+B7+IFN-gamma and IL2+B7 groups showed significant decreases of tumor volume (P<0.01), and the survival rates were 25% and 12.5%, respectively. Furthermore, IL2+B7+IFN-gamma, IL2+B7 and IL2 groups showed significant deacreases in the number of lung metastases (P<0.01).These results suggests that the vaccinations of irradiated tumor cells of transfected IL-2 and B7 gene, and pretreatment with IFN-r, showed the strongest antitumor effects in mice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Phase I・II clinical trial of fusion vaccine combined with chemotherapy
-
批准号:19591494
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.83万
-
财政年份:2007
-
负责人:OKINAGA Kota
-
依托单位:
Tumor specific vaccine therapy by fusion cells of dendritic cells and tumor cells
-
批准号:13671255
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2001
-
负责人:OKINAGA Kota
-
依托单位:
Development of BRM sensitivity test using the Th1/Th2 balance and clinical application
-
批准号:10671135
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.05万
-
财政年份:1998
-
负责人:OKINAGA Kota
-
依托单位:
Detection of tumor cells in peripheral blood by PCR-SSCP using the oncogene as DNA marker
-
批准号:05671028
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.34万
-
财政年份:1993
-
负责人:OKINAGA Kota
-
依托单位:
国内基金
海外基金
登录
查看更多内容
益气养阴方影响U1SnRNP经IL-2/STAT5b通路调节上皮性卵巢癌术后患者外周B/T免疫平衡的机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:蒋莎
-
依托单位:
靶向浆细胞治疗系统性红斑狼疮的新型IL-2融合蛋白的开发及机制研究
-
批准号:2024Y9116
-
项目类别:省市级项目
-
资助金额:25.0万元
-
批准年份:2024
-
负责人:马文娟
-
依托单位:
PIK3CD获功能突变调控IL-2受体抑制γδT细胞肿瘤杀伤功能的机制研究
-
批准号:CSTB2023NSCQ-MSX0444
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2023
-
负责人:张敏
-
依托单位:
PIK3CD功能获得性突变调控IL-2受体抑制γδ T细胞杀伤功能的机制研究
-
批准号:82302058
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:张敏
-
依托单位:
超声促IL-2/CCL22纳米粒淋巴结靶向递送抑制心脏移植物血管病变的研究
-
批准号:82302229
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:吴纯
-
依托单位:
低剂量IL-2调控CD8+T细胞线粒体生物发生治疗系统性红斑狼疮并HBV感染的作用与机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:陈家丽
-
依托单位:
可共价结合CD25的IL-2开发及其在自身免疫病治疗中的应用
-
批准号:82271831
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:张博
-
依托单位:
CD4+T细胞p53依赖的NonO/IL-2轴在SLE发病中的机制研究
-
批准号:82201995
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:李新宇
-
依托单位:
IL-6阻断IL-2/CD122信号通路影响双阴性T细胞功能促进PBC发病的研究
-
批准号:82100633
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:吕婷婷
-
依托单位:
CD4+T细胞过表达HDAC1导致系统性红斑狼疮IL-2信号通路缺陷的致病效应和分子机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:孙晓麟
-
依托单位: